# PharmacyFlow milestone report

## BLK-002-I3 local authoring completion — 2026-10-26

Status: **LOCAL AUTHORING COMPLETE — INACTIVE — UNEXECUTED — REVIEW REQUIRED**. Added injected gateway/operator façades, shared stable-principal/typed-fingerprint contracts, exact ambiguity recovery, normalized-email/applicant-key binding, deep immutable results, append-only operation/decision evidence design, two unmapped executor roles, five mutually exclusive façade grants and forward-only migration `000030`. Fresh focused results: gateway 16/16, operator 17/17, I3 static 42/42, corrected I2 44/44, issuer 39/39 + 53/53, onboarding 28/28 and focused TypeScript PASS.

The migration fails closed on pre-I3 rows rather than inventing context/provenance. It remains unexecuted. Real provider/Auth/workload identity, PostgreSQL syntax/RLS/effective privileges/concurrency, browser and deployment acceptance are not verified. AUTH-02 remains deferred. Stop for independent review of `PHARMACYFLOW_BLK002_I3_COMPLETION_REPORT_PF-SUP-2026-10-26-02.md` and the scoped manifest.

## PF-SUP-2026-10-26-01 I2 correction disposition

The independently reproduced I2 model defects are locally corrected: effect/result/audit commit is staged atomically in the model; recovery uses current trusted action-specific authorization; fingerprints are computed from explicit typed commands rather than caller hashes; credential rotation preserves stable actor identity without preserving stale authority; and canonical results are deep-immutable. Fresh results are 44/44 corrected I2 injected, 39/39 issuer injected, 53/53 issuer static/synchronous, 28/28 onboarding static/synchronous and focused strict TypeScript PASS.

This is specification evidence only. Migrations `000028`/`000029` remain unchanged and unexecuted, sequential ordering is not PostgreSQL concurrency proof, and I3 façade/role/grant/migration work has not started. Stop for incremental independent review of the corrected manifest/package.

## BLK-002-I2 gateway/provider security design — 2026-10-26

Status: **CONDITIONAL**. The local design, feasibility analysis and injected contract model are complete. The selected architecture is a PharmacyFlow-controlled gateway authenticated by a dedicated short-lived workload principal to a narrow issuer façade; applicant-authenticated recovery/consumption and separately authenticated platform-operator decisions remain distinct. ADM-01 and REV-01 are fully specified as policy contracts. Fresh focused results are 28/28 I2 injected, 39/39 issuer injected, 53/53 issuer static/synchronous and 28/28 onboarding static/synchronous.

The decisive unresolved dependency is whether the chosen provider/platform can prove non-client-writable exact-operation identity creation/recovery and narrow workload authentication. The existing schema also lacks attributable operator/revocation decisions and a stable prospective pharmacy context. BLK-002-I3 is proposed as separately authorized local source and forward-only migration authoring; it is not yet authorized. PostgreSQL/RLS/concurrency, Auth/provider, browser and deployment acceptance remain **NOT VERIFIED**, and PharmacyFlow is not MVP or production ready.

Consolidated design: `docs/development/PHARMACYFLOW_BLK002_I2_GATEWAY_PROVIDER_SECURITY_DESIGN_2026-10-26.md`. Incremental evidence/review request: `docs/development/PHARMACYFLOW_BLK002_I2_REVIEW_PACKAGE_2026-10-26.md`.

## PF-SUP-2026-10-25-12 review disposition

The 30-file correction snapshot received scoped independent review. BLK-015–017 are **LOCALLY REVIEWED** at source/synthetic level and no new P0/P1 was identified. Real browser, Auth/PostgREST, SQL, concurrency and cleanup remain unverified. BLK-012's incremental-review gate is complete, but broader release assembly, MVP acceptance, staging, commit, deployment and execution acceptance remain open and separately authorized. The sole P2 package inconsistency is corrected: `AUTHORIZATION_REQUEST.md` now names reviewed runner hash `13f2344fe831aba67fbf2c94a8fe9884dd202651faeae7ce424ba019f8fe5cf9`; `d44b5e…` is historical.

The decision-ready next-phase packet is `docs/development/PHARMACYFLOW_OWNER_DECISION_PACKET_2026-10-25.md`. It recommends BLK-002 onboarding-contract local authoring as the smallest next milestone after explicit owner authorization. AUTH-02 remains **NOT RUN — OWNER DEFERRED**.

## Milestone: M1 — baseline audit and architecture reconciliation

**Status:** COMPLETE for local static reconciliation; independent review pending.

PF-SUP-2026-10-23-08 closes the M1 inventory/documentation batch only. It does not accept M2–M5 implementation, database effects, browser behavior, deployment, or commercial authority.

### -07/-08 finding reconciliation

No repository artifact explicitly named PF-SUP-2026-10-23-07 or -08 before this batch. The owner’s current -08 directive is the primary correction record; prior evidence is the -06 decision/progress set plus independently reviewed Phase B checkpoints. The absence of a stored -07 report is recorded as a provenance limitation, not silently reconstructed.

| Finding | Evidence | Accountable owner | Disposition at -08 | Next gate |
|---|---|---|---|---|
| M1 inventory versus acceptance | Eight `docs/mvp` records; `PHARMACYFLOW_CAPABILITY_MATRIX.md`; older development roadmap | Engineering records; GPT-6 reviews | **CORRECTED DOCUMENTATION:** M1 inventory complete; implementation/acceptance statuses unchanged | Incremental independent review of this overlay |
| Commercial delivery/transaction idempotency | M-3 unique provider transaction; `PHARMACYFLOW_COMMERCIAL_ARCHITECTURE.md`; specification model | Product owner for policy; engineering for protected design | **DESIGN CORRECTED / NOT IMPLEMENTED:** delivery IDs separated; canonical transaction/invoice/entitlement uniqueness and lock order specified | Independent security/financial design review, then protected-implementation approval |
| Aggregate credit lifecycle | Commercial architecture and `scripts/specification/commercial-model*` | Product owner for valuation/policy; engineering for design | **DESIGN CORRECTED / NOT IMPLEMENTED:** tenant/asset ownership and available/reserved/consumed/reversed/recovery states specified | Resolve valuation/holding/cap/expiry/annual choices, then protected design review |
| Referral uniqueness across policy/settlements | Commercial architecture and synthetic model | Product owner for policy | **DESIGN CORRECTED / NOT IMPLEMENTED:** one `(program, referred organization)` award with immutable snapshot and deterministic settlement | Same owner decisions; rewards remain inactive |
| Offline-grant proof | `PHARMACYFLOW_FORWARD_CONTRACT_DESIGNS.md:50-58`; BLK-013 | Product owner selects policy; security/financial review | **OPEN — OWNER DECISION:** no signed-grant proof; conservative first-server-acceptance retained | Explicit owner choice and separately approved protocol/proof batch |
| Deployment ordering | `PHARMACYFLOW_DEPLOYMENT_RECOVERY_PLAN.md`; BLK-014 | Release owner; AUTH-03 access owner | **LOCALLY CORRECTED / NOT EXECUTED:** disposable acceptance now precedes Dev inspection/rollout; AUTH-03 remains blocked by access method | Fresh review, then resolve read-only method and obtain step-specific authorizations |
| Invalidated-action busy state | `capabilityBoundary.ts` plus Customers/Suppliers/Devices/Cash effects; BLK-015 | Engineering; browser acceptance reviewer | **LOCALLY REVIEWED / EXTERNAL EVIDENCE OPEN:** invalidation clears busy state and rejects stale completion | Later isolated browser acceptance remains separate |
| Concurrency evidence | `scripts/acceptance/concurrency-harness.ps1`; Gate B/Refund runners; BLK-016 | Financial/security reviewer | **PREPARED / NOT RUN:** deterministic requirements preserved; admin/service SQL is not user authorization proof | Owner-authorized disposable SQL concurrency plus independent evidence review |
| Grant/RLS/PostgREST evidence | Hardened `status-v2-postgrest.mjs`; BLK-016 | Security reviewer | **LOCALLY REVIEWED / NOT RUN:** 23/23 injected orchestration; decoded claims explicitly are not signature proof | AUTH-02 remains owner-deferred |
| Edge cleanup safety | Hardened shared cleanup; BLK-017 | Engineering | **LOCALLY REVIEWED / NOT RUN:** bidirectional known-user guard and original-root proof pass injected/static checks | AUTH-02 remains owner-deferred |

Every open item is also represented in `PHARMACYFLOW_BLOCKER_REGISTER.md`. Documentation/design changes do not resolve source/runtime evidence dependencies.

### Starting state

- Authorized workspace: `C:\Users\Flourish\Documents\GitHub\pflow-production claude vs`.
- Branch/HEAD: `main` / `d145324be6d5f1c787bceab6baf27ca0ce375eeb`.
- The tree already contained extensive modified/untracked work from Phase B, Refund V2, auth/subscription/Admin, acceptance runners, documents, and manifests. It was preserved without staging, resetting, stashing, cleaning, or overwriting.
- Existing checkpoints through PF-SUP-2026-10-23-06 were treated as evidence, then checked against focused current source paths. A broad audit was not repeated.

### Architecture inventory

| Layer | Current repository evidence | Finding |
|---|---|---|
| SaaS client | root `package.json`, `src/main.tsx`, `src/App.tsx`, `src/components`, `src/lib` | Canonical React 19 + TypeScript + Vite 8 application with Supabase JS, tenant-aware auth states, pharmacy workflow modules, and local synthetic runner. |
| Admin Support | `apps/pharmacy-flow-admin/package.json`, `app`, `components/Dashboard.tsx`, `lib/admin-data-readiness.ts` | Separate Next.js 15 application; active dashboard is read-only/fail-closed and does not substitute fixtures for authoritative data. |
| Auth/tenant | `src/contexts/AuthContext.tsx`, M-1/M-2/M-16, onboarding adapter/tests | Active membership resolution and multi-pharmacy selection exist. Atomic OWNER bootstrap remains design-only; invitation client integration follows sealed M-16. |
| Database | `supabase/migrations` | 27 sealed historical SQL migrations through M-25; one additive status-v2 SQL artifact is authored/unexecuted; one TypeScript security test resides in the directory. No ledger/execution state was inspected. |
| Edge gateways | `supabase/functions/sync-push-sale`, `sync-push-return`, `sync-push-return-v2` | Sale, legacy return, and Refund V2 gateways exist in source; deployment status is unknown. |
| Offline/POS | `src/lib/offline`, `src/lib/pos`, `src/components/OfflineSyncRuntime.tsx`, POS UI | IndexedDB queue/drafts, signing, leases, bounded initialization, immutable recovery, and stale-result adapters exist locally. Real browser/database acceptance remains unrun. |
| Core operations | inventory, supplier, customer, sales, cash, reports modules and tests | Broad workflow implementation exists; financial/stock/RLS/branch acceptance is mostly target-dependent. |
| Subscription | sealed M-3/M-16 plus `src/lib/subscription` | Legacy plan/subscription/payment tables and advisory client lifecycle/capability containment exist. APP-02's authoritative server enforcement is not implemented. |
| Billing/referral | M-3 generic tables; disconnected Admin fixture file | No active Paystack/provider abstraction or referral/credit ledger implementation was found. Fixture prices/referrals are not product contracts. |
| Build/mobile/ops | Vite/Express config, Admin Next config, deployment/recovery docs | Browser build paths exist. Canonical Android project, current deployment, monitoring, backup rehearsal, and performance evidence are absent/unverified. |

### Protected-contract register

- Sealed historical migrations M-1 through M-25 are immutable. The unexecuted status-v2 artifact may only change within its already authorized review scope before execution.
- M-18 unified sale replay/hash/checkout conflict/rollback semantics and M-20..M-25 Refund V2 contracts are preserved.
- Tenant/branch isolation, cashier-own-sale/permitted-return visibility, platform-admin boundaries, SECURITY DEFINER ownership/search paths/grants, device P-256 signatures, nonce ordering/consumption, and stable operation IDs remain security-critical.
- Durable payload bytes, frozen timestamps, customer/payment evidence, lease transaction completion, retired checkout ownership, and conservative unknown/recovery states remain Phase B invariants.
- APP-02 client checks are containment, never server authorization. Browser payment success and client timestamps are not settlement/eligibility proof.
- Admin fixture data, source-string assertions, and local mocks never establish authoritative records or deployed behavior.

### Implementation summary

- Added the six persistent Milestone 1 registers plus the TEST-01 disposable authorization proposal and COM-01/02/03 commercial architecture under `docs/mvp/`.
- Recorded AUTH-01–05, APP-01–07, COM-01–03, and TEST-01 with explicit execution boundaries.
- Classified current capabilities with concrete source evidence and separated missing commercial functionality from disconnected fixtures.
- Created a blocker register, dependency-aware five-milestone roadmap, evidence register, protected-contract register, and proposed sequence.
- The initial M1 inventory pass did not modify product source, package metadata, migrations, external runners, or existing development records.
- PF-SUP-2026-10-23-08 adds only specification-model source/test files outside runtime, tightens commercial design, corrects acceptance evidence classes/cleanup claims, and prepares a supplemental review manifest. No billing integration or server authority was added.

### Security assessment

No protected contract was changed. The main current risk is evidence insufficiency rather than a newly demonstrated source defect: database/RLS/concurrency, real-browser storage/lifecycle, remote compatibility, and commercial server enforcement are unverified. Billing/referral components must be server-authoritative and remain inactive until separately approved.

### Authorization status

Permitted and performed: read-only repository/source inspection and local documentation creation.

Not performed: database/SQL/migration, Docker, service/port/network, credential, browser datastore, remote inspection, deployment, payment/referral activation, installation, destructive operation, or Git mutation. StoreFlow was not accessed or probed.

### Open blockers

See `PHARMACYFLOW_BLOCKER_REGISTER.md`. Consequential items are BLK-001 (protected acceptance), BLK-002/003 (onboarding/entitlement server contracts), BLK-004/005 (commercial choices), BLK-006 (billing/referral implementation), BLK-007 (Dev read-only method), BLK-009 (dependency snapshot), and BLK-012 (independent/release review).

### Next action

The design-only COM-01/COM-02/COM-03 package is now recorded in `PHARMACYFLOW_COMMERCIAL_ARCHITECTURE.md`, and TEST-01 is recorded in `PHARMACYFLOW_DISPOSABLE_TEST_AUTHORIZATION.md`. Submit this incremental baseline/design register and the prior AUTH checkpoint for independent GPT-6 review, then address focused nonprotected M2 gaps. Protected implementation, external acceptance, Git execution, and deployment remain separate owner gates.

## PF-SUP-2026-10-25-09 incremental report

- Resolved the demonstrated BLK-017 local source dependency without reopening Phase B or Refund V2 contracts. A shared cleanup module now guards explicit fixture pharmacies, Auth identities, and Auth-trigger bootstrap pharmacies; preserves a scenario failure through cleanup; restores replication role; and requires a parsed zero-root proof.
- EDGE-001, EDGE-002 and EDGE-003 use that cleanup on success and failure. EDGE-002 no longer assumes historical EDGE-001 UUIDs: it creates and commits its own initial operation before exact replay, changed-hash conflict, and nonce-replay assertions.
- Fresh local evidence consists only of JavaScript syntax checks, injected/static cleanup tests, target-guard tests, source-claim verification, and whitespace inspection. Edge, Auth, SQL, Docker, ports, services, credentials, browser storage, migration and concurrency execution were not performed.
- M3/M5 remain partial. PF-SUP-2026-10-25-12 later completed the scoped source review; genuine status-v2 PostgREST evidence and every AUTH-02 protected gate remain pending and owner-deferred.

## PF-SUP-2026-10-25-10 incremental report

- Prepared the missing status-v2 PostgREST acceptance runner without executing it. Its 23 scenarios cover anonymous grant denial; inactive and cross-tenant present/absent indistinguishability; OWNER/MANAGER/PHARMACIST visibility; cashier-owned sale and permitted-return visibility; unrelated denial; incomplete and legacy evidence; and structurally empty authorized absence.
- The runner accepts no service-role credential and creates no Auth user. It requires eight distinct short-lived target-signed JWTs with fixed fixture subjects, validates subject/role/audience/issuer/expiry, and verifies owner-approved runner/migration hashes before Docker inspection or HTTP access.
- Local injected tests exercise token/source preflight, zero-external-access abort, exact PostgREST paths/headers, denial shapes, committed provenance and absence non-disclosure. This is synthetic preparation, not PostgREST, RLS, grant, database or Auth acceptance.
- BLK-016 remains **BLOCKED BY EXECUTION AUTHORIZATION** because the runner, migration, committed fixture and deterministic concurrency harness are unexecuted. Owner approval must name the disposable target, signed-token issuance method, source hashes, commands, credentials and cleanup.

## PF-SUP-2026-10-25-11 local closure report

- BLK-016 and BLK-017 source defects are locally corrected, with fresh injected/specification evidence recorded in `PHARMACYFLOW_TEST_EVIDENCE.md`. Their real PostgREST/Auth/database/concurrency/cleanup acceptance remains **NOT RUN — OWNER DEFERRED** under AUTH-02.
- Commercial settlement and credit behavior now has an explicit monotonic transition table, stable compensation replay/conflict rules, cumulative reversal bounds, ambiguity holds and a single lock hierarchy. These are design-model claims, not PostgreSQL concurrency evidence.
- The demonstrated capability-invalidation busy-state defect is corrected in production components and covered for scope, expiry and renewal. Actual React/browser acceptance remains separate.
- Disposable acceptance now precedes any Dev inspection/rollout in the plan. AUTH-03 remains **BLOCKED — ACCESS METHOD** and deployment remains unauthorized.
- No protected operation occurred. PF-SUP-2026-10-25-12 reviewed the runner/cleanup corrections; that review did not create or inherit execution approval.
